Synthesis of Novel 1,4-Benzodiazepine-3,5-dione Derivatives: Reaction of 
2-Aminobenzamides under Bargellini Reaction Conditions

Mohammad Mahdavi; Mehdi Asadi; Mina Saeedi; Zahra Rezaei; Hooman Moghbel; Alireza Foroumadi; Abbas Shafiee

doi:10.1055/s-0032-1317297

Synlett, Table of Contents

Synlett 2012; 23(17): 2521-2525
DOI: 10.1055/s-0032-1317297

letter

Synthesis of Novel 1,4-Benzodiazepine-3,5-dione Derivatives: Reaction of 2-Aminobenzamides under Bargellini Reaction Conditions

Mohammad Mahdavi

^aDepartment of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran 14176, Iran Fax: +98(21)66461178 Email: ashafiee@ams.ac.ir

,

Mehdi Asadi

^bSchool of Chemistry, University College of Science, University of Tehran, PO Box 14155-6455, Tehran, Iran

,

Mina Saeedi

^aDepartment of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran 14176, Iran Fax: +98(21)66461178 Email: ashafiee@ams.ac.ir

,

Zahra Rezaei

^aDepartment of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran 14176, Iran Fax: +98(21)66461178 Email: ashafiee@ams.ac.ir

,

Hooman Moghbel

^bSchool of Chemistry, University College of Science, University of Tehran, PO Box 14155-6455, Tehran, Iran

,

Alireza Foroumadi

^aDepartment of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran 14176, Iran Fax: +98(21)66461178 Email: ashafiee@ams.ac.ir

,

Abbas Shafiee*

^aDepartment of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran 14176, Iran Fax: +98(21)66461178 Email: ashafiee@ams.ac.ir

› Author Affiliations

Abstract

All articles of this category

Abstract

In this paper, we report on a user-friendly synthesis of 1,4-benzodiazepine-3,5-dione derivatives via Bargellini-type reaction. The corresponding products were obtained using various 2-aminobenzamides under Bargellini reaction conditions, in good yields without unfavorable side reaction.

Key words

Bargellini-type reaction - 1,4-benzodiazepine-3,5-diones - 2-aminobenzamides - heterocycles - dichloro epoxide

Full Text

References

References and Notes
1 Bargellini G. Gazz. Chim. Ital. 1906; 36: 329
2 Korger G. Chem. Ber. 1963; 96: 10
3 Corey EJ, Link JO. J. Am. Chem. Soc. 1992; 114: 1906
4 Butcher KJ, Hurst J. Tetrahedron Lett. 2009; 50: 2497

5a Lai JT. J. Org. Chem. 1980; 45: 754
5b Lai JT. Synthesis 1981; 41
5c Lai JT. Synthesis 1984; 122
5d Lai JT. Synthesis 1984; 124

6 Recent synthetic application of Bargellini reaction: Snowden TS. ARKIVOC 2012; (ii): 24
7 Hosseini-Zare MS, Mahdavi M, Saeedi M, Asadi M, Javanshir S, Shafiee A, Foroumadi A. Tetrahedron Lett. 2012; 51: 3448
8 Tahghighi A, Razmi S, Mahdavi M, Foroumadi P, Ardestani SK, Emami S, Kobarfard F, Dastmalchi S, Shafiee A, Foroumadi A. Eur. J. Med. Chem. 2012; 50: 124
9 Hamadi H, Khoobi M, Hossaini Z, Shafiee A. Mol. Diversity 2011; 15: 35
10 Jamalian A, Miri R, Firuzi O, Amini M, Moosavi-Movahedi AA, Shafiee A. J. Iran. Chem. Soc. 2011; 8: 983
11 Akbarzadeh T, Fallah-Tafti A, Samadi N, Foroumadi A, Amanlou M, Faramarzi MA, Shafiee A. DARU 2010; 18: 118
12 Evans BE, Rittle KE, Bock MG, DiPardo RM, Freidinger RM, Whitter WL, Lundell GF, Veber DF, Anderson PS, Chang RS. L, Lotti VJ, Cerino DJ, Chen TB, Kling PJ, Kunkel KA, Springer JP, Hirshfield J. J. Med. Chem. 1988; 31: 2235
13 Chiu TRosenberg H. C. Trends Pharm. Sci. 1983; 4: 348
14 Sternbach LH. J. Med. Chem. 1979; 22: 1

15a Parks DJ, LaFrance LV, Calvo RR, Milkiewicz KL, Gupta V, Lattanze J, Ramachandren K, Carver TE, Petrella EC, Cummings MD, Maguire D, Grasberger BL, Lu T. Bioorg. Med. Chem. Lett. 2005; 15: 765
15b Cummings MD, Schubert C, Parks DJ, Calvo RR, LaFrance LV, Lattanze J, Milkiewicz KL, Lu T. Chem. Biol. Drug Des. 2006; 67: 201

16 Horton DA, Bourne GT. Chem. Rev. 2003; 103: 893
17 Hulme C, Peng J, Tang SY, Burns CJ, Morize I, Labaudiniere R. J. Org. Chem. 1998; 63: 8021
18 Keating TA, Armstrong RW. J. Org. Chem. 1996; 61: 8935
19 Kalinski C, Umkehrer M, Ross G, Kolb J, Burdacka C, Hiller W. Tetrahedron Lett. 2006; 47: 3423
20 Jadidi K, Ghahremanzadeh R, Asgari D, Eslami P, Arvin-Nezhad H. Monatsh. Chem. 2008; 139: 1229
21 Ciofi L, Trabocchi A, Lalli C, Menchi G, Guarna A. Org. Biomol. Chem. 2012; 10: 2780
22 Gärtner S. Justus Liebigs Ann. Chem. 1904; 332: 226
23 Wiklund P, Rogers-Evans M, Bergman J. J. Org. Chem. 2004; 69: 6371
24 Osman AN, El-Gendy AA, Omar RH, Wagdy L, Omar AH. Boll. Chim. Farm. 2002; 141: 8
25 Synthesis of 1,2-Dihydro-4H-benzo[e][1,4]diazepine-3,5-dione Derivatives – General Procedure A mixture of anhydrous acetone–ethyl methyl ketone (40 mmol, 3 mL) and CHCl₃ (60 mmol, 4.6 mL) in the presence of NaOH powder (60 mmol, 2.3 g) was stirred at r.t. for 10 min (in the case of ethylmethyl ketone it should be stirred for 15 min). After this time, 2-aminobenzamide derivatives (2 mmol) were added to the reaction mixture and it continued for the corresponding time, as indicated in Table 1, at the same temperature. Upon completion of reaction the solution was extracted with CHCl₃ (3 × 20 mL). The organic layer was separated, dried (Na₂SO₄), and concentrated in vacuo to yield the crude product which was purified by column chromatography eluting with PE–EtOAc (6:1). 1,2-Dihydro-2,2-dimethyl-4H-benzo[e][1,4]diazepine-3,5-dione (11a) Yield 0.17 g (85%); white crystals; mp 228–230 °C. IR (KBr): 3337 (NH), 1698 (C=O), 1636 (C=O) cm^–1. ¹H NMR (500 MHz, CDCl₃): δ = 1.48 (s, 6 H, CH₃), 4.11 (s, 1 H, NH), 6.78 (d, J = 7.6 Hz, 1 H, H₉), 7.02 (t, J = 7.6 Hz, 1 H, H₇), 7.40 (td, J = 7.6, 1.4 Hz, 1 H, H₈), 8.20 (dd, J = 7.6, 1.4 Hz, 1 H, H₆), 8.11 (s, 1 H, NH). ¹³C NMR (125 MHz, CDCl₃): δ = 23.5, 56.5, 116.8, 118.6, 120.0, 131.8, 134.0, 146.8, 165.0, 173.6. Anal. Calcd for C₁₁H₁₂N₂O₂: C, 64.69; H, 5.92; N, 13.72. Found: C, 64.80; H, 6.10; N, 13.55. 2-Ethyl-1,2-dihydro-2-methyl-4H-benzo[e][1,4]diazepine-3,5-dione (11b) Yield 0.18 g (85%); white crystals; mp 160–162 °C. IR (KBr): 3359 (NH), 1698 (C=O), 1645 (C=O) cm^–1. ¹H NMR (500 MHz, CDCl₃): δ = 0.87 (t, J = 7.4 Hz, 3 H, CH₂CH₃ ), 1.48 (s, 3 H, CH₃), 1.75 (dq, J = 14.8, 7.4 Hz, 1 H, CH₂ CH₃), 1.80 (dq, J = 14.8, 7.4 Hz, 1 H, CH ₂CH₃), 4.16 (s, 1 H, NH), 6.79 (d, J = 7.5 Hz, 1 H, H₉), 7.00 (t, J = 7.5 Hz, 1 H, H₇), 7.40 (dt, J = 7.5, 1.3 Hz, 1 H, H₈), 8.19 (dd, J = 7.5, 1.3 Hz, 1 H, H₆), 8.21 (s, 1 H, NH). ¹³C NMR (125 MHz, CDCl₃): δ = 7.5, 22.7, 27.9, 60.8, 120.3, 120.6, 133.1, 134.8, 145.5, 164.3, 173.8. Anal. Calcd for C₁₂H₁₄N₂O₂: C, 66.04; H, 6.47; N, 12.84. Found: C, 65.90; H, 6.55; N, 12.99. 4-Benzyl-1,2-dihydro-2,2-dimethyl-4H-benzo[e][1,4]-diazepine-3,5-dione (11c) Yield 0.23 g (80%); white crystals; mp 100–102 °C. IR (KBr): 3335 (NH), 1698 (C=O), 1650 (C=O) cm^–1. ¹H NMR (500 MHz, CDCl₃): δ = 1.35 (s, 6 H, CH₃), 5.03 (s, 2 H, NCH₂), 6.80 (s, 1 H, NH), 6.99–7.05 (m, 2 H, H₉, H_4′), 7.17–7.19 (m, 3 H, H₇, H_2′, H_6′), 7.27–7.37 (m, 3 H, H₈, H_3′, H_5′), 7.98 (d, J = 7.2 Hz, 1 H, H₆). ¹³C NMR (125 MHz, CDCl₃): δ = 23.3, 48.5, 56.5, 116.4, 117.9, 119.1, 126.7, 126.9, 128.2, 132.2, 133.9, 138.2, 145.8, 167.6, 176.4. Anal. Calcd for C₁₈H₁₈N₂O₂: C, 73.45; H, 6.16; N, 9.52. Found: C, 73.30; H, 6.40; N, 10.21. 4-Benzyl-2-ethyl-1,2-dihydro-2-methyl-4H-benzo[e]-[1,4]diazepine-3,5-dione (11d) Yield 0.23 g (75%); white crystals; mp 134–136 °C. IR (KBr): 3467 (NH), 1695 (C=O), 1641 (C=O) cm^–1. ¹H NMR (500 MHz, CDCl₃): δ = 0.78 (t, J = 7.4 Hz, 3 H, CH₂CH ₃), 1.46 (s, 3 H, CH₃), 1.77–1.83 (m, 2 H, CH ₂CH₃), 4.53 (s, 1 H, NH), 5.13 (d, J = 15.7 Hz, 1 H, NCH₂), 5.31 (d, J = 15.7 Hz, 1 H, NCH₂), 6.77 (d, J = 8.1 Hz, 1 H, H₉), 6.89 (t, J = 7.5 Hz, 1 H, H₇), 6.98–7.00 (m, 1 H, H_4′), 7.06–7.11 (m, 2 H, H_2′, H_6′), 7.29–7.39 (m, 3 H, H₈, H_3′, H_5′), 8.11 (d, J = 7.5 Hz, 1 H, H₆). ¹³C NMR (125 MHz, CDCl₃): δ = 8.4, 20.3, 28.3, 47.1, 61.2, 118.1, 119.0, 119.6, 126.5, 126.8, 127.7, 129.2, 132.6, 133.2, 134.2, 134.9, 144.7, 167.5, 173.7. Anal. Calcd for C₁₉H₂₀N₂O₂: C, 74.00; H, 6.54; N, 9.08. Found: C, 73.80; H, 6.35; N, 9.30. 4-(2-Chlorobenzyl)-1,2-dihydro-2,2-dimethyl-4H-benzo[e][1,4]diazepine-3,5-dione (11e) Yield 0.27 g (82%); yellow crystals; mp 130–132 °C. IR (KBr): 3338 (NH), 1697 (C=O), 1622 (C=O) cm^–1. ¹H NMR (500 MHz, CDCl₃): δ = 1.51 (s, 6 H, CH₃), 4.37 (s, 1 H, NH), 5.26 (s, 2 H, NCH₂), 6.76 (dd, J = 8.2, 1.0 Hz, 1 H, H₉), 6.95 (ddd, J = 8.2, 6.5, 1.1 Hz, 1 H, H_4′), 7.05 (t, J = 7.0 Hz, 1 H, H₇), 7.14–7.17 (m, 2 H, H_5′, H_6′), 7.34 (dd, J = 6.5, 3.0 Hz, 1 H, H_3′), 7.38 (ddd, J = 8.2, 7.0, 1.5 Hz, 1 H, H₈), 8.20 (dd, J = 7.0, 1.5 Hz, 1 H, H₆). ¹³C NMR (125 MHz, CDCl₃): δ = 24.7, 47.3, 58.0, 118.4, 119.1, 119.9, 126.6, 127.0, 127.9, 129.4, 132.9, 133.5, 134.3, 135.1, 144.8, 167.6, 173.5. MS: m/z (%) = 330 (17) [M + 2]⁺, 328 (51) [M⁺], 300 (20), 203 (25), 160 (100). 132 (85), 92 (28), 65 (20). Anal. Calcd for C₁₈H₁₇ClN₂O₂: C, 65.75; H, 5.21; N, 8.52. Found: C, 65.90; H, 5.45; N, 8.40. 4-(2-Chlorobenzyl)-2-ethyl-1,2-dihydro-2-methyl-4H-benzo[e][1,4]diazepine-3,5-dione (11f) Yield 0.26 g (75%); yellow crystals; mp 134–136 °C. IR (KBr): 3350 (NH) 1697 (C=O), 1623 (C=O) cm^–1. ¹H NMR (500 MHz, CDCl₃): δ = 0.81 (t, J = 7.4 Hz, 3 H, CH₂CH ₃), 1.49 (s, 3 H, CH₃), 1.80 (dq, J = 14.8, 7.4 Hz, 1 H, CH ₂CH₃), 1.87 (dq, J = 14.8, 7.4 Hz, 1 H, CH ₂CH₃), 4.50 (s, 1 H, NH), 5.19 (d, J = 15.7 Hz, 1 H, NCH₂), 5.36 (d, J = 15.7 Hz, 1 H, NCH₂), 6.77 (d, J = 8.0 Hz, 1 H, H₉), 6.92 (t, J = 7.5 Hz, 1 H, H_4′), 7.05 (t, J = 8.2 Hz, 1 H, H₇), 7.12–7.18 (m, 2 H, H_5′, H_6′), 7.32–7.39 (m, 2 H, H₈, H_3′), 8.16 (d, J = 8.2 Hz, 1 H, H₆). ¹³C NMR (125 MHz, CDCl₃): δ = 7.5, 27.2, 47.2, 61.3, 119.1, 119.7, 126.6, 127.1, 127.8, 128.6, 129.0, 129.3, 132.8, 133.3, 134.2, 144.7, 167.5, 173.7. Anal. Calcd for C₁₉H₁₉ClN₂O₂: C, 66.57; H, 5.59; N, 8.17. Found: C, 66.80; H, 5.40; N, 7.95. 4-(4-Methoxybenzyl)-1,2-dihydro-2,2-dimethyl-4H-benzo[e][1,4]diazepine-3,5-dione (11g) Yield 0.24 g (75%); white crystals; mp 120–122 °C. IR (KBr): 3329 (NH), 1694 (C=O), 1609 (C=O) cm^–1. ¹H NMR (500 MHz, CDCl₃): δ = 1.43 (s, 6 H, CH₃), 3.77 (s, 3 H, OCH₃), 4.42 (s, 1 H, NH), 5.12 (s, 2 H, NCH₂), 6.70 (d, J = 8.1 Hz, 1 H, H₉), 6.82 (d, J = 8.5 Hz, 2 H, H_3′, H_5′), 6.91 (t, J = 7.6 Hz, 1 H, H₇), 7.31–7.34 (m, 3 H, H₈, H_2′, H_6′), 8.20 (dd, J = 7.6, 1.4 Hz, 1 H, H₆). ¹³C NMR (125 MHz, CDCl₃): δ = 24.4, 48.7, 55.1, 57.7, 113.6, 114.1, 118.4, 118.8, 119.4, 129.4, 130.2, 133.4, 134.0, 144.5, 158.5, 167.8, 173.0. Anal. Calcd for C₁₉H₂₀N₂O₃: C, 70.35; H, 6.21; N, 8.64. Found: C, 70.50; H, 6.44; N, 8.80. 4-(4-Methoxybenzyl)-2-ethyl-1,2-dihydro-2-methyl-4H-benzo[e][1,4]diazepine-3,5-dione (11h) Yield 0.24 g (70%); white crystals; mp 110–111 °C. IR (KBr): 3320 (NH), 1698 (C=O), 1617 (C=O) cm^–1. ¹H NMR (500 MHz, CDCl₃): δ = 0.71 (t, J = 7.4 Hz, 3 H, CH₂CH ₃), 1.47 (s, 3 H, CH₃), 1.67 (dq, J = 14.8, 7.4 Hz, 1 H, CH ₂CH₃), 1.76 (dq, J = 14.8, 7.4 Hz, 1 H, CH ₂CH₃), 3.76 (s, 3 H, OCH₃), 4.43 (s, 1 H, NH), 5.09 (d, J = 14.0 Hz, 1 H, NCH₂), 5.15 (d, J = 14.0 Hz, 1 H, NCH₂), 6.71 (d, J = 7.3 Hz, 1 H, H₉), 6.81 (d, J = 8.6 Hz, 2 H, H_3′, H_5′), 6.90 (t, J = 7.3 Hz, 1 H, H₇), 7.32 (dt, J = 7.3, 1.5 Hz, 1 H, H₈), 7.36 (d, J = 8.6 Hz, 2 H, H_2′, H_6′), 8.19 (dd, J = 7.3, 1.5 Hz, 1 H, H₆). ¹³C NMR (125 MHz, CDCl₃): δ = 7.4, 23.1, 26.9, 48.7, 55.1, 60.9, 113.5, 118.3, 118.8, 119.3, 129.8, 130.2, 133.2, 134.0, 144.3, 158.5, 167.7, 173.1. MS: m/z (%) = 338 (76 [M⁺], 281 (20), 217 (20), 174 (59), 146 (52), 121 (100), 77 (25). Anal. Calcd for C₂₀H₂₂N₂O₃: C, 70.99; H, 6.55; N, 8.28. Found: C, 71.15; H, 6.80; N, 8.35. 4-[(Furan-2-yl)-methyl]-1,2-dihydro-2,2-dimethyl-4H-benzo[e][1,4]diazepine-3,5-dione (11i) Yield 0.18 g (65%); white crystals; mp 103–105 °C. IR (KBr): 3366 (NH), 1695 (C=O), 1625 (C=O) cm^–1. ¹H NMR (500 MHz, CDCl₃): δ = 1.45 (s, 6 H, CH₃), 4.37 (s, 1 H, NH), 5.17 (s, 2 H, NCH₂), 6.28–6.29 (m, 2 H, furan), 6.71 (dd, J = 7.6, 0.9 Hz, 1 H, H₉), 6.92 (dt, J = 7.6, 0.9 Hz, 1 H, H₇), 7.30 (dd, J = 3.0, 1.0 Hz, 1 H, furan), 7.34 (dt, J = 7.6, 1.4 Hz, 1 H, H₈), 8.21 (dd, J = 7.6, 1.4 Hz, 1 H, H₆). ¹³C NMR (125 MHz, CDCl₃): δ = 24.5, 42.1, 57.8, 108.1, 110.2, 118.2, 118.9, 119.6, 133.5, 134.1, 141.6, 144.6, 151.4, 167.2, 173.2. MS: m/z (%) = 284 (35) [M⁺], 257 (15), 241 (20), 203 (20), 160 (100), 132 (90), 96 (71), 53 (28). Anal. Calcd for C₁₆H₁₆N₂O₃: C, 67.59; H, 5.67; N, 9.85. Found: C, 67.66; H, 5.86; N, 10.00. 2-Ethyl-4-[(furan-2-yl)-methyl]-1,2-dihydro-2-methyl-4H-benzo[e][1,4]diazepine-3,5-dione (11j) Yield 0.18 g (60%); white crystals; mp 102–104 °C. IR (KBr): 3336 (NH), 1697 (C=O), 1621 (C=O) cm^–1. ¹H NMR (500 MHz, CDCl₃): δ = 0.73 (t, J = 7.4 Hz, 3 H, CH₂CH ₃), 1.49 (s, 3 H, CH₃), 1.66 (dq, J = 14.8, 7.4 Hz, 1 H, CH ₂CH₃), 1.80 (dq, J = 14.8, 7.4 Hz, 1 H, CH ₂CH₃), 4.37 (s, 1 H, NH), 5.09 (d, J = 14.7 Hz, 1 H, NCH₂), 5.23 (d, J = 14.7 Hz, 1 H, NCH₂), 6.28–6.31 (m, 2 H, furan), 6.72 (d, J = 8.0 Hz, 1 H, H₉), 6.91 (t, J = 7.7 Hz, 1 H, H₇), 7.31–7.35 (m, 2 H, H₈, furan), 8.20 (d, J = 7.7 Hz, 1 H, H₆). ¹³C NMR (125 MHz, CDCl₃): δ = 7.3, 23.2, 26.9, 42.1, 61.1, 108.5, 110.2, 118.1, 118.9, 119.5, 133.3, 134.1, 141.5, 144.4, 151.4, 167.1, 173.1. MS: m/z (%) = 298 (65) [M⁺], 271 (14), 241 (42), 217 (26), 174 (97), 146 (75), 81 (100), 53 (45). Anal. Calcd for C₁₇H₁₈N₂O₃: C, 68.44; H, 6.08; N, 9.39. Found: C, 68.25; H, 5.90; N, 9.15. 4-(3,5-Dimethoxyphenethyl)-1,2-dihydro-2,2-dimethyl-4H-benzo[e][1,4]diazepine-3,5-dione (11k) Yield 0.26 g (70%); white crystals; mp 125–127 °C. IR (KBr): 3367 (NH), 1687 (C=O), 1634 (C=O) cm^–1. ¹H NMR (500 MHz, CDCl₃): δ = 1.26 (s, 6 H, CH₃), 2.88 (t, J = 7.8 Hz, 2 H, NCH₂CH ₂), 3.85 (s, 6 H, OCH₃), 4.13 (t, J = 7.8 Hz, 2 H, NCH ₂CH₂), 4.45 (s, 1 H, NH), 6.72–6.80 (m, 4 H, H₉, H_2′, H_4′, H_6′), 6.90 (t, J = 7.5 Hz, 1 H, H₇), 7.32 (t, J = 7.5 Hz, 1 H, H₈), 8.12 (d, J = 7.5 Hz, 1 H, H₆). ¹³C NMR (125 MHz, CDCl₃): δ = 24.5, 34.9, 48.2, 55.7, 55.8, 57.8, 111.1, 112.1, 118.8, 119.5, 120.7, 132.4, 133.1, 134.0, 144.4, 147.4, 148.6, 168.1, 173.2. Anal. Calcd for C₂₁H₂₄N₂O₄: C, 68.46; H, 6.57; N, 7.60. Found: C, 68.15; H, 6.30; N, 7.77.

Supplementary Material

Supporting Information